| Infinite Health Collaborative, Pa | |
|
4200 Dahlberg Dr Suite 300 Golden Valley MN 55422-4840 | |
| (952) 512-5600 | |
| (952) 512-5651 |
| Full Name | Infinite Health Collaborative, Pa |
|---|---|
| Speciality | Orthopaedic Surgery |
| Location | 4200 Dahlberg Dr, Golden Valley, Minnesota |
| Authorized Official Name and Position | Aaron W Johnson (CEO) |
| Authorized Official Contact | 9524567316 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Infinite Health Collaborative, Pa 3500 American Blvd W Ste 300 Bloomington MN 55431-4442 Ph: (952) 512-5600 | Infinite Health Collaborative, Pa 4200 Dahlberg Dr Suite 300 Golden Valley MN 55422-4840 Ph: (952) 512-5600 |
| NPI Number | 1164474250 |
|---|---|
| Provider Enumeration Date | 05/17/2006 |
| Last Update Date | 01/17/2024 |
| Medicare PECOS PAC ID | 1052225042 |
|---|---|
| Medicare Enrollment ID | O20040209000574 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164474250 | NPI | - | NPPES |
| Provider Name | Brian T Oneill |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1700897162 PECOS PAC ID: 5991619660 Enrollment ID: I20031117000687 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Patricia M Pettit |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1922002658 PECOS PAC ID: 8628975703 Enrollment ID: I20031217000139 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott M Jensen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154305662 PECOS PAC ID: 6800709395 Enrollment ID: I20040113000063 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tanya A Reckinger |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699863803 PECOS PAC ID: 8022910835 Enrollment ID: I20040122000838 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Myriah M Hanno |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1417929670 PECOS PAC ID: 4587567854 Enrollment ID: I20040202000789 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel T Chow |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1154398881 PECOS PAC ID: 8325931405 Enrollment ID: I20040203000842 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul R Diekmann |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1669490439 PECOS PAC ID: 2668366139 Enrollment ID: I20040214000168 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael David Garr |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1457325904 PECOS PAC ID: 9537066196 Enrollment ID: I20040224000029 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Russell L Wavrin |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1962479071 PECOS PAC ID: 2668368853 Enrollment ID: I20040225000142 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher P Meyer |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1669585816 PECOS PAC ID: 5698665461 Enrollment ID: I20040316001189 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Patrick B Ebeling |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1013930858 PECOS PAC ID: 2466342258 Enrollment ID: I20040316001288 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristopher Gerald Balgaard |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1053495564 PECOS PAC ID: 1759373566 Enrollment ID: I20040401000458 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jancy A Eddy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487736013 PECOS PAC ID: 4981691342 Enrollment ID: I20040428000019 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Neil R Johnson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1144243973 PECOS PAC ID: 2769479625 Enrollment ID: I20040430000677 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew F Arthur |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1720017544 PECOS PAC ID: 9739177890 Enrollment ID: I20040505001503 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joseph T Teynor |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1124137302 PECOS PAC ID: 9830083179 Enrollment ID: I20040514001018 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rebecca S Mattison |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1093775736 PECOS PAC ID: 2567445513 Enrollment ID: I20040610000730 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thomas K Comfort |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1669443495 PECOS PAC ID: 2961485784 Enrollment ID: I20040611000216 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Edward W Szalapski |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1538262084 PECOS PAC ID: 5799679023 Enrollment ID: I20040611001298 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ann Therese Kaminski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396744306 PECOS PAC ID: 6406830736 Enrollment ID: I20040615000993 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brad R Moser |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770699555 PECOS PAC ID: 4284619610 Enrollment ID: I20040621001158 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristen M Shedd |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1881886422 PECOS PAC ID: 9537144837 Enrollment ID: I20040621001835 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Denise Marion Ingram |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1962518571 PECOS PAC ID: 0547245763 Enrollment ID: I20040622000933 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laura Loeding Bechtold |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144336702 PECOS PAC ID: 9234114190 Enrollment ID: I20040623001119 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Susan E Anderson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194831743 PECOS PAC ID: 7012992985 Enrollment ID: I20040623001147 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christian M Dubois |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1336145952 PECOS PAC ID: 8224008636 Enrollment ID: I20040730000950 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Roderick L Youngdahl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821193681 PECOS PAC ID: 5496727059 Enrollment ID: I20040812000869 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah J Jenks |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1053338137 PECOS PAC ID: 9335114503 Enrollment ID: I20040831001062 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul M Cammack |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1962413799 PECOS PAC ID: 5698742393 Enrollment ID: I20040913000917 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael J Cumming |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1649258526 PECOS PAC ID: 7012977077 Enrollment ID: I20041013001345 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Wanda J Lickteig |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104932730 PECOS PAC ID: 5597726216 Enrollment ID: I20041025001097 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Corey A Wulf |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1811968365 PECOS PAC ID: 7618938259 Enrollment ID: I20041026000811 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robert V Knowlan |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1609872381 PECOS PAC ID: 2961316054 Enrollment ID: I20041120000141 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gregory N Lervick |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1881701829 PECOS PAC ID: 4385600014 Enrollment ID: I20041204000287 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christie S Heikes |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1154541035 PECOS PAC ID: 4789642646 Enrollment ID: I20041222000666 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jasmin Grace V Ramirez |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1588628135 PECOS PAC ID: 3274582648 Enrollment ID: I20050113000139 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James W Matheson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831142892 PECOS PAC ID: 4587614045 Enrollment ID: I20050124000429 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jacqueline A Luong |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1598874778 PECOS PAC ID: 1153371281 Enrollment ID: I20050126001077 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Peter A Bretzman |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1902884117 PECOS PAC ID: 4082528013 Enrollment ID: I20050222000031 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher R Pegram |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730190612 PECOS PAC ID: 1951354695 Enrollment ID: I20050223000061 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael R Meisterling |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1346247665 PECOS PAC ID: 1254397318 Enrollment ID: I20050304000091 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melinda Susan Ament |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962588525 PECOS PAC ID: 1153375795 Enrollment ID: I20050308000244 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sheryl A Louie |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336145937 PECOS PAC ID: 1153376835 Enrollment ID: I20050315000926 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bonnie L Shelley |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154426856 PECOS PAC ID: 6204881527 Enrollment ID: I20050318000568 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark J Froemke |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841214723 PECOS PAC ID: 7416902622 Enrollment ID: I20050321000320 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James C Clark |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871562330 PECOS PAC ID: 6103872072 Enrollment ID: I20050323001061 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jason L Eggers |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1275581795 PECOS PAC ID: 0143276923 Enrollment ID: I20050324000504 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sheila R Goodman |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1144224965 PECOS PAC ID: 5991751414 Enrollment ID: I20050329000170 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Teresa M Pattison |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477551679 PECOS PAC ID: 0345296653 Enrollment ID: I20050329001080 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rochelle L Lindow |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811092455 PECOS PAC ID: 6608814504 Enrollment ID: I20050421000230 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa A Smith |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790894012 PECOS PAC ID: 7214975796 Enrollment ID: I20050425000749 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David A Willey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1043207681 PECOS PAC ID: 3375582786 Enrollment ID: I20050426000596 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nancy W Schmidt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275596660 PECOS PAC ID: 7517907827 Enrollment ID: I20050505001009 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Frank B Norberg |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1326154931 PECOS PAC ID: 4587607486 Enrollment ID: I20050602000049 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth Klodas |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1194792978 PECOS PAC ID: 6305881459 Enrollment ID: I20050621000059 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael T Carey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043304207 PECOS PAC ID: 7517903644 Enrollment ID: I20050629000778 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | John T Chow |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1851365985 PECOS PAC ID: 7618913252 Enrollment ID: I20050705000661 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Barbara C Toppin |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1356327688 PECOS PAC ID: 6305816570 Enrollment ID: I20050713000449 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robert M Barnett |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164535308 PECOS PAC ID: 4183650658 Enrollment ID: I20050715000450 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael J Dixey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902860216 PECOS PAC ID: 3274569660 Enrollment ID: I20050718000394 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kari Lynn Cox |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609894617 PECOS PAC ID: 1951338136 Enrollment ID: I20050719001095 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sou-pan Wu |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1114993961 PECOS PAC ID: 9931137213 Enrollment ID: I20050728000378 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David R Anderson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1770690687 PECOS PAC ID: 2264460211 Enrollment ID: I20050801000150 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rebekah R Ormsby |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1962489443 PECOS PAC ID: 2961430764 Enrollment ID: I20050802001095 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah B Schmitz-burns |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1548211485 PECOS PAC ID: 1759311723 Enrollment ID: I20050818000925 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | William T Simonet |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1851330088 PECOS PAC ID: 2668403619 Enrollment ID: I20050830000070 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Johannes C Coetzee |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1891729000 PECOS PAC ID: 2961433818 Enrollment ID: I20050830000842 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Julie A Stauffer |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245349455 PECOS PAC ID: 2466484977 Enrollment ID: I20050906000842 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott Anseth |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1942213384 PECOS PAC ID: 0042290645 Enrollment ID: I20050906000859 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan M Cooper |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1720028830 PECOS PAC ID: 1456384890 Enrollment ID: I20050915000503 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ellen R Shammash |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1760455208 PECOS PAC ID: 9032143722 Enrollment ID: I20050922000169 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Deborah A Lensing |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538250154 PECOS PAC ID: 1658305925 Enrollment ID: I20050926000760 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Allan F Hunt |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1134103633 PECOS PAC ID: 5395797229 Enrollment ID: I20050927001086 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Barry W Griffith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851475164 PECOS PAC ID: 6103851514 Enrollment ID: I20051004000637 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robert F Laprade |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1477658771 PECOS PAC ID: 2163447376 Enrollment ID: I20051006000826 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jon P Smith |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1780695007 PECOS PAC ID: 9739104720 Enrollment ID: I20051010000073 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel P Spielman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063413250 PECOS PAC ID: 3971529751 Enrollment ID: I20051020000774 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Angela M Stock |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891801486 PECOS PAC ID: 7012936560 Enrollment ID: I20051115000190 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gary E Wyard |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1659487239 PECOS PAC ID: 8325062367 Enrollment ID: I20060118000169 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark D Fischer |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1801807177 PECOS PAC ID: 2062427503 Enrollment ID: I20060220000531 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Stephen L Olmsted |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1326060427 PECOS PAC ID: 9032124581 Enrollment ID: I20060220000555 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David Gesensway |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1386655629 PECOS PAC ID: 1456366905 Enrollment ID: I20060220000590 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul C Biewen |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1316053051 PECOS PAC ID: 2062428444 Enrollment ID: I20060222000204 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul W Breyen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1235242827 PECOS PAC ID: 8426064718 Enrollment ID: I20060223000379 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Catherine G Carrabre |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366507626 PECOS PAC ID: 5395751184 Enrollment ID: I20060303000075 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michelle N Griffin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407592595 PECOS PAC ID: 1850308479 Enrollment ID: I20060307000525 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa M Matheson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407047467 PECOS PAC ID: 4688681786 Enrollment ID: I20060315000134 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jessica L Olderness |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265549950 PECOS PAC ID: 1355358466 Enrollment ID: I20060315000262 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tiffany E Rodman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891702080 PECOS PAC ID: 9032126784 Enrollment ID: I20060321000465 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Regina N Cho |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1316976970 PECOS PAC ID: 5294762860 Enrollment ID: I20060413000068 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Allison K West |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1528019676 PECOS PAC ID: 2365445392 Enrollment ID: I20060814000072 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joseph P Nemanich |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1851363378 PECOS PAC ID: 3870596497 Enrollment ID: I20060821000015 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa C Richardson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578582235 PECOS PAC ID: 3779586219 Enrollment ID: I20060823000024 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Heather L Schroeder |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851301766 PECOS PAC ID: 4385648377 Enrollment ID: I20060906000037 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeffrey J Mair |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1154364669 PECOS PAC ID: 3678577301 Enrollment ID: I20060911000524 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christine A Reeb |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1558464339 PECOS PAC ID: 7517962046 Enrollment ID: I20060915000410 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael D Smith |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1528032315 PECOS PAC ID: 1254336555 Enrollment ID: I20060920000132 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher J Kuhn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760590103 PECOS PAC ID: 7810992500 Enrollment ID: I20061003000034 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ron D Fischer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902873847 PECOS PAC ID: 0941233175 Enrollment ID: I20061003000066 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael J Slavics |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902990476 PECOS PAC ID: 0244236693 Enrollment ID: I20061009000209 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth Gc Haglind |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1720186042 PECOS PAC ID: 7113923566 Enrollment ID: I20061009000240 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul L Ramnarine |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427157353 PECOS PAC ID: 9931105798 Enrollment ID: I20061018000486 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kathleen Cram |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710086095 PECOS PAC ID: 4688671464 Enrollment ID: I20061109000162 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maurie S Steinley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578594792 PECOS PAC ID: 0547268153 Enrollment ID: I20061115000034 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer M Erdmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588756688 PECOS PAC ID: 4284632696 Enrollment ID: I20061120000200 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael J Stay |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215027669 PECOS PAC ID: 6406855865 Enrollment ID: I20061212000440 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jill K Monson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1235234998 PECOS PAC ID: 2062411341 Enrollment ID: I20061214000261 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kimberly R Anderson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609955087 PECOS PAC ID: 7719987833 Enrollment ID: I20070112000366 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laurie C Humiston |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295823458 PECOS PAC ID: 1254332042 Enrollment ID: I20070122000398 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jodi B Chaplin |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134182322 PECOS PAC ID: 9133120942 Enrollment ID: I20070122000613 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew R Harrison |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1396768180 PECOS PAC ID: 0749281400 Enrollment ID: I20070123000418 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Trisha D Mellesmoen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1548356132 PECOS PAC ID: 1052312279 Enrollment ID: I20070130000553 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian A Lehr |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154332369 PECOS PAC ID: 3375550841 Enrollment ID: I20070207000472 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer H Ambur |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1215003306 PECOS PAC ID: 7911979927 Enrollment ID: I20070227000116 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sara C Lumby |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1477683670 PECOS PAC ID: 8729044466 Enrollment ID: I20070410000365 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher M Larson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1396763314 PECOS PAC ID: 1153426101 Enrollment ID: I20070419000265 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah A Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144359373 PECOS PAC ID: 4981700127 Enrollment ID: I20070503000468 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rochelle Ann Wolfe |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1417164005 PECOS PAC ID: 9931207289 Enrollment ID: I20070611000020 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James B Williams |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1881617306 PECOS PAC ID: 5991804718 Enrollment ID: I20070620000164 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Steven D Meletiou |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1447322011 PECOS PAC ID: 2062461395 Enrollment ID: I20070730000798 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Timothy G Schaefer |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1346325487 PECOS PAC ID: 0042301863 Enrollment ID: I20070808000791 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Karie K Nash |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770680076 PECOS PAC ID: 6709882822 Enrollment ID: I20070822000982 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hope E Frisch |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1396943726 PECOS PAC ID: 7315039153 Enrollment ID: I20070823000838 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James H Zavoral |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1588675789 PECOS PAC ID: 7618069386 Enrollment ID: I20070827000091 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Corey N Fett |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174715361 PECOS PAC ID: 1355433046 Enrollment ID: I20070827000274 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Frederick B Harris |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1881716827 PECOS PAC ID: 3173617784 Enrollment ID: I20070913000193 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Patrick F Okeefe |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1720125180 PECOS PAC ID: 1153416466 Enrollment ID: I20071002000425 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Steven R Schneider |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750390472 PECOS PAC ID: 7416043252 Enrollment ID: I20071010000158 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric Richard Nelson |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1619946811 PECOS PAC ID: 5092803056 Enrollment ID: I20071109000028 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Xochill A Thalhuber |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427055888 PECOS PAC ID: 1951391283 Enrollment ID: I20071120000331 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ann Christine Lowry |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1174532881 PECOS PAC ID: 7214825777 Enrollment ID: I20080131000515 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cyril F Kruse |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1467487579 PECOS PAC ID: 0941397665 Enrollment ID: I20080227000150 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott A Wilkins |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225008634 PECOS PAC ID: 2365400413 Enrollment ID: I20080430000332 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew C Grupa |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972767374 PECOS PAC ID: 0648345322 Enrollment ID: I20080814000310 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erik M Wetter |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1285784892 PECOS PAC ID: 5092880542 Enrollment ID: I20080818000456 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul H Sufka |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1962695023 PECOS PAC ID: 7416022520 Enrollment ID: I20080822000715 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric E Kirksson |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1184870255 PECOS PAC ID: 0648346122 Enrollment ID: I20080908000028 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mitchell J Kary |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1861658742 PECOS PAC ID: 2567538838 Enrollment ID: I20080910000445 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kimberly A Gerten |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1083658181 PECOS PAC ID: 5092741488 Enrollment ID: I20081006000032 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah E Wilcox |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255509659 PECOS PAC ID: 0244300473 Enrollment ID: I20081007000350 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mary T Dahling |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1801863436 PECOS PAC ID: 8820166366 Enrollment ID: I20081009000829 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jay S Johnson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1295706059 PECOS PAC ID: 8224196209 Enrollment ID: I20081020000461 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan S Carey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952557936 PECOS PAC ID: 9638237589 Enrollment ID: I20081021000519 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David A Steele |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487816872 PECOS PAC ID: 3678632767 Enrollment ID: I20081104000524 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mary Beth Schiffer |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427076694 PECOS PAC ID: 5597825224 Enrollment ID: I20081125000338 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sara M Jorud |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821186628 PECOS PAC ID: 5395806574 Enrollment ID: I20081205000583 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jay D Schindler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164641924 PECOS PAC ID: 6103987201 Enrollment ID: I20081208000576 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy M Boyden Hoekstra |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013950369 PECOS PAC ID: 6406919299 Enrollment ID: I20090105000424 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | John A Schwartz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1083635585 PECOS PAC ID: 8224061452 Enrollment ID: I20090109000233 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark A Urban |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1154332401 PECOS PAC ID: 8022902360 Enrollment ID: I20090302000409 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy Stuke |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205906583 PECOS PAC ID: 2365508900 Enrollment ID: I20090305000286 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ashley Caroline Walker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558512475 PECOS PAC ID: 0446316038 Enrollment ID: I20090305000717 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jason A Barry |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1295830339 PECOS PAC ID: 0547326167 Enrollment ID: I20090306000206 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carrie J Carpenter |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487755146 PECOS PAC ID: 7618024407 Enrollment ID: I20090414000342 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Beth A Pesta |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659526903 PECOS PAC ID: 3173671567 Enrollment ID: I20090422000593 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael J Nemanich |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1932157682 PECOS PAC ID: 0941397814 Enrollment ID: I20090608000314 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laura D Koch |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1992753537 PECOS PAC ID: 1850488727 Enrollment ID: I20090608000360 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Edward W Kelly |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1871541672 PECOS PAC ID: 3577650449 Enrollment ID: I20090608000494 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Owen R Oneill |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1568410454 PECOS PAC ID: 0143126326 Enrollment ID: I20090608000516 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul R Langer |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1790733442 PECOS PAC ID: 1557411857 Enrollment ID: I20090608000533 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Meredith Kasbohm |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1881886018 PECOS PAC ID: 3870645302 Enrollment ID: I20090715000057 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Julie A Heckathorne |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1285830182 PECOS PAC ID: 9537211925 Enrollment ID: I20090715000750 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Becky R Stealy |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942439906 PECOS PAC ID: 6002969557 Enrollment ID: I20090730000287 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jason P Dieterle |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1376730069 PECOS PAC ID: 3779637400 Enrollment ID: I20090903000110 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | John W Bottoms |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144451675 PECOS PAC ID: 6608921044 Enrollment ID: I20090908000477 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Steven W Meisterling |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1467660613 PECOS PAC ID: 4981770344 Enrollment ID: I20090909000200 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Krista J Olsen |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1447393962 PECOS PAC ID: 1557417441 Enrollment ID: I20090917000400 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Allison Vargen Mikota |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104053198 PECOS PAC ID: 8820134109 Enrollment ID: I20090930000671 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark J Mangine |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841420882 PECOS PAC ID: 1759427313 Enrollment ID: I20091013000099 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maryclare K Mccarthy |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1124076096 PECOS PAC ID: 7214821552 Enrollment ID: I20091019000688 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan R. Karlstad |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1205832896 PECOS PAC ID: 0042226342 Enrollment ID: I20091229000272 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicholas J Meyer |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1659378255 PECOS PAC ID: 1850307158 Enrollment ID: I20091229000354 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Loren N Vorlicky |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1831205616 PECOS PAC ID: 0042300865 Enrollment ID: I20100114000226 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan P Asp |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1467463802 PECOS PAC ID: 0143114496 Enrollment ID: I20100114000487 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott R Mcgarvey |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1205943255 PECOS PAC ID: 5496897381 Enrollment ID: I20100114000560 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Randall A Lewis |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1093738759 PECOS PAC ID: 8820001498 Enrollment ID: I20100116000306 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | John R Kearns |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1467465807 PECOS PAC ID: 1951443720 Enrollment ID: I20100118000197 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Timothy J. Panek |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1699771386 PECOS PAC ID: 8325952419 Enrollment ID: I20100119000106 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrea M. Saterbak |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1184620858 PECOS PAC ID: 3779497862 Enrollment ID: I20100119000120 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Troy A Vargas |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1023014784 PECOS PAC ID: 6204842503 Enrollment ID: I20100119000512 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David C Fey |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1932123908 PECOS PAC ID: 7113069584 Enrollment ID: I20100122000560 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thomas N Conner |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1609887520 PECOS PAC ID: 0042104390 Enrollment ID: I20100128000952 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Patrick G Kraft |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1619988490 PECOS PAC ID: 9739073073 Enrollment ID: I20100128000967 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul J Crowe |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1184635922 PECOS PAC ID: 7810881158 Enrollment ID: I20100128000971 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Benjamin Gulli |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1629089099 PECOS PAC ID: 5597855312 Enrollment ID: I20100202000011 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Peter D Holmberg |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1972521748 PECOS PAC ID: 6305933029 Enrollment ID: I20100205000663 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David R Edwards |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1548376239 PECOS PAC ID: 2466595855 Enrollment ID: I20100208000309 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher J Bailey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760718084 PECOS PAC ID: 3870636186 Enrollment ID: I20100209000617 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lindsay J Darrah |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1427193549 PECOS PAC ID: 2668515842 Enrollment ID: I20100210000544 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jessica L Grajczyk |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1154531192 PECOS PAC ID: 6406999697 Enrollment ID: I20100210000625 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brett T Gemlo |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1437168101 PECOS PAC ID: 0143118604 Enrollment ID: I20100215000742 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kayvon S Riggi |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1104839521 PECOS PAC ID: 9133219959 Enrollment ID: I20100217000142 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael P Spencer |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1386653947 PECOS PAC ID: 8921996489 Enrollment ID: I20100226000685 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paul G Dworak |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1437265295 PECOS PAC ID: 4284528530 Enrollment ID: I20100302000160 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David F Ruebeck |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1578670956 PECOS PAC ID: 2163472291 Enrollment ID: I20100304001083 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kara E Pettigrew |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548244791 PECOS PAC ID: 3577646934 Enrollment ID: I20100310000582 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy J Thorsen |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1215945944 PECOS PAC ID: 1951368141 Enrollment ID: I20100330000128 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mary Anne Jacob |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1659348399 PECOS PAC ID: 3274425608 Enrollment ID: I20100408000100 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Juan C Angelats |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1598730756 PECOS PAC ID: 9537295126 Enrollment ID: I20100408000142 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa M Baker |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1912970179 PECOS PAC ID: 3870544869 Enrollment ID: I20100428000975 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Richard B Gosen |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1346212867 PECOS PAC ID: 8325099310 Enrollment ID: I20100430000440 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy M Brown |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1447223615 PECOS PAC ID: 7416908405 Enrollment ID: I20100430000456 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melinda M Gillis |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457320038 PECOS PAC ID: 1557499712 Enrollment ID: I20100507000639 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Stephanie A Rice |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1881667061 PECOS PAC ID: 3870544877 Enrollment ID: I20100512000336 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Frank J B Czerniecki |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1558333070 PECOS PAC ID: 0244281236 Enrollment ID: I20100512000490 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laura Ed Scherf |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1396714754 PECOS PAC ID: 2365438561 Enrollment ID: I20100514000218 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Barbara J Sterner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891764163 PECOS PAC ID: 5092701292 Enrollment ID: I20100514000254 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa L Benedetto |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447213244 PECOS PAC ID: 1254469901 Enrollment ID: I20100517000757 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David E Olson |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1497830319 PECOS PAC ID: 8921137456 Enrollment ID: I20100521000435 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anthony T Nagy |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487888780 PECOS PAC ID: 3779612072 Enrollment ID: I20100525000789 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Shannon L Rechtiene |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184712390 PECOS PAC ID: 8628107836 Enrollment ID: I20100526001041 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thomas Jason Cesarz |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1275645814 PECOS PAC ID: 5294806386 Enrollment ID: I20100722000984 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Justin A Walker |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1851529770 PECOS PAC ID: 9830213115 Enrollment ID: I20100824001001 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Suzin Cho |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1093798480 PECOS PAC ID: 3173562170 Enrollment ID: I20100914000901 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kirk A Shibley |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1821071291 PECOS PAC ID: 0244230126 Enrollment ID: I20100914000968 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aimee Song |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1831172220 PECOS PAC ID: 7517967490 Enrollment ID: I20100914001005 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrea Jeanne Flom |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1467429175 PECOS PAC ID: 7113075227 Enrollment ID: I20100921000982 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan H Sampson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790006476 PECOS PAC ID: 7810189644 Enrollment ID: I20101012000065 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah Grahn |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1932226701 PECOS PAC ID: 6204996705 Enrollment ID: I20101012001198 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robert P Himmerick |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134389778 PECOS PAC ID: 0648462317 Enrollment ID: I20101013000583 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lindsey M Wedoe |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578878070 PECOS PAC ID: 0547453177 Enrollment ID: I20101014001490 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David J Gerlach |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1376749358 PECOS PAC ID: 9931393113 Enrollment ID: I20101101001609 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David E Hartigan |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1467680322 PECOS PAC ID: 0547454555 Enrollment ID: I20101103001413 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Richard A Davis |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1417044538 PECOS PAC ID: 6800867706 Enrollment ID: I20101111001518 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah E Sievert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366755316 PECOS PAC ID: 7719173467 Enrollment ID: I20101122000153 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy J Engebretson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1083808869 PECOS PAC ID: 5991991408 Enrollment ID: I20101123000814 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kyle R Nyquist |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790090777 PECOS PAC ID: 1052509056 Enrollment ID: I20101216001113 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brandon E Schomberg |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700190634 PECOS PAC ID: 6406044783 Enrollment ID: I20101230000901 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Matt A Anderson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457375917 PECOS PAC ID: 9537358726 Enrollment ID: I20110104000251 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tonia J Flategraff |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295040947 PECOS PAC ID: 2264621127 Enrollment ID: I20110106001130 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott W Peterson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841507324 PECOS PAC ID: 9537348677 Enrollment ID: I20110121000618 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Adam J Wolf |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1881903698 PECOS PAC ID: 7618157017 Enrollment ID: I20110201000908 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alixandra S Crepeau |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1730368713 PECOS PAC ID: 1850467143 Enrollment ID: I20110201000954 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelly J Soukup |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669419610 PECOS PAC ID: 7618158155 Enrollment ID: I20110216001081 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Linda J Maag |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1801846761 PECOS PAC ID: 8022166131 Enrollment ID: I20110222001188 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth P Elfstrand |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1124078159 PECOS PAC ID: 9931257045 Enrollment ID: I20110222001203 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelly M Borreson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043511058 PECOS PAC ID: 4385825298 Enrollment ID: I20110225000355 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brent D Jorud |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619064029 PECOS PAC ID: 4789865411 Enrollment ID: I20110228000899 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Matthew A Hofkens |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1568605210 PECOS PAC ID: 9931383635 Enrollment ID: I20110404000871 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Garry M Banks |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1649220849 PECOS PAC ID: 3678468998 Enrollment ID: I20110406000879 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Wanda P Adefris |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1235115577 PECOS PAC ID: 3577533744 Enrollment ID: I20110418000531 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melissa C Olson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720054752 PECOS PAC ID: 4486687613 Enrollment ID: I20110504000669 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | William C Whisler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790768364 PECOS PAC ID: 7517867757 Enrollment ID: I20110512000226 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katherine Marie Jacobs |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1184816506 PECOS PAC ID: 0941486237 Enrollment ID: I20110523000194 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Stephanie S Skeba |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1669765566 PECOS PAC ID: 8527246081 Enrollment ID: I20110705000084 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole M Dahmes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427286426 PECOS PAC ID: 8325216302 Enrollment ID: I20110718000577 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott Myron Holthusen |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1093924276 PECOS PAC ID: 7214069442 Enrollment ID: I20110722000244 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel J Marek |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1912190075 PECOS PAC ID: 3375711104 Enrollment ID: I20110722000269 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole J Weiers |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740578699 PECOS PAC ID: 5799955795 Enrollment ID: I20110831000133 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Julie E Wenda |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114215977 PECOS PAC ID: 8921278854 Enrollment ID: I20110831000559 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric M Seppelt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851687826 PECOS PAC ID: 3971773573 Enrollment ID: I20110908001767 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christine C Jensen |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1598876823 PECOS PAC ID: 3173794567 Enrollment ID: I20110914000853 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kimberly C Naruko Stewart |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1780881532 PECOS PAC ID: 4880865948 Enrollment ID: I20110921000230 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lauren A Callahan |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1477711158 PECOS PAC ID: 4284805177 Enrollment ID: I20110926000808 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrea L Lewis |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780962381 PECOS PAC ID: 8628240199 Enrollment ID: I20111004000881 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelin E Schultz |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1528265378 PECOS PAC ID: 8022280122 Enrollment ID: I20111014000326 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole A Weir |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225316771 PECOS PAC ID: 1153594882 Enrollment ID: I20111025000708 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maria C Ryan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306163571 PECOS PAC ID: 8921271271 Enrollment ID: I20111101000569 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Steven W Kraushaar |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841578325 PECOS PAC ID: 4880867977 Enrollment ID: I20111107000253 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alissa R Ahmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629356076 PECOS PAC ID: 9335312313 Enrollment ID: I20111108000538 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michelle A Reiner |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437225125 PECOS PAC ID: 7517075856 Enrollment ID: I20111111000488 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carly L. Mattson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1467735407 PECOS PAC ID: 4486828282 Enrollment ID: I20111112000075 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Heidi C Natterstad |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982889275 PECOS PAC ID: 0547435513 Enrollment ID: I20111203000045 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laura C Russell |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1689608523 PECOS PAC ID: 5890798086 Enrollment ID: I20111206000541 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joshua K Rolfes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770862187 PECOS PAC ID: 3274706767 Enrollment ID: I20111212000514 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric G Hanson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518153444 PECOS PAC ID: 7214102458 Enrollment ID: I20111216000062 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Angie R Swanson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376549436 PECOS PAC ID: 3577553809 Enrollment ID: I20120109000898 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megin John |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215228648 PECOS PAC ID: 7214198886 Enrollment ID: I20120409000659 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Matthew F Omahoney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1124201330 PECOS PAC ID: 9931361847 Enrollment ID: I20120509000655 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Marty M Mertens |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1558555896 PECOS PAC ID: 6406019587 Enrollment ID: I20120530000297 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jacob J Haws |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811263551 PECOS PAC ID: 3577728567 Enrollment ID: I20120625000449 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Peter C Sanders |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1972734820 PECOS PAC ID: 4082879549 Enrollment ID: I20120706000498 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicholas N Holmes |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1740458835 PECOS PAC ID: 8628250891 Enrollment ID: I20120723000772 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Adam J Bakker |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1538359757 PECOS PAC ID: 1658528021 Enrollment ID: I20120821000350 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark Y Sun |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1487617593 PECOS PAC ID: 3577710524 Enrollment ID: I20120827000072 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ashley Emiko Takekawa |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750646048 PECOS PAC ID: 6901055003 Enrollment ID: I20121004000863 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Marc C Osborne |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1326226507 PECOS PAC ID: 5193975720 Enrollment ID: I20121017000298 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Renata Braudy |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821159831 PECOS PAC ID: 2466550777 Enrollment ID: I20121114000606 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maggie L Dewitz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1447506522 PECOS PAC ID: 4183875370 Enrollment ID: I20121116000281 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole A Wheeler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669728440 PECOS PAC ID: 8527219500 Enrollment ID: I20121126000202 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Craig A Ringsven |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336334374 PECOS PAC ID: 4082866124 Enrollment ID: I20121218000302 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Crystal D Tainter |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669563292 PECOS PAC ID: 5395999395 Enrollment ID: I20130128000526 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Peter David Aggen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376560706 PECOS PAC ID: 2860426129 Enrollment ID: I20130220000227 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Seth D Engberg |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699010132 PECOS PAC ID: 8022263268 Enrollment ID: I20130326000496 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christian A Dawson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1073870812 PECOS PAC ID: 3173760238 Enrollment ID: I20130508000428 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark L Thurnbeck |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1285722355 PECOS PAC ID: 4880831692 Enrollment ID: I20130515000642 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan D Horazdovsky |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1417196148 PECOS PAC ID: 4082853585 Enrollment ID: I20130613000113 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric M Deal |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1326242371 PECOS PAC ID: 1658528088 Enrollment ID: I20130802000082 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy T Moeller |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1578706610 PECOS PAC ID: 5496902561 Enrollment ID: I20130813000933 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian P Bjerke |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1043445612 PECOS PAC ID: 0547416133 Enrollment ID: I20130813000966 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Laura C Sampers |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336582691 PECOS PAC ID: 6103068341 Enrollment ID: I20130816000707 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeffrey D Seybold |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1730390238 PECOS PAC ID: 6709020050 Enrollment ID: I20130926000521 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jason S Holm |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1184832578 PECOS PAC ID: 9335397413 Enrollment ID: I20130930000595 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maura M Hartigan |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1720344203 PECOS PAC ID: 2860627742 Enrollment ID: I20131031000097 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Karen E Edmonson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144517509 PECOS PAC ID: 5294905287 Enrollment ID: I20131112001661 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Caroline P Haakenson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871747808 PECOS PAC ID: 8224208442 Enrollment ID: I20131118000005 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bryan D Dejarlais |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730515719 PECOS PAC ID: 8426284043 Enrollment ID: I20131203001777 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Steven P Churchill |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659601508 PECOS PAC ID: 8123151115 Enrollment ID: I20131217000024 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeffrey Kent Sletten |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891934188 PECOS PAC ID: 0345401006 Enrollment ID: I20131217000127 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erik G Peterson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417289216 PECOS PAC ID: 4284861048 Enrollment ID: I20131226001089 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Abby K Lipanot |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174945315 PECOS PAC ID: 3779711635 Enrollment ID: I20140123000046 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michele L Jacobson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487751558 PECOS PAC ID: 8426286246 Enrollment ID: I20140124000031 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark D Schroeckenstein |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427101286 PECOS PAC ID: 7517114424 Enrollment ID: I20140224001651 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Krista L Siewert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538444062 PECOS PAC ID: 3870723562 Enrollment ID: I20140225000627 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | A B M Masudur Rahman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295027514 PECOS PAC ID: 5496987364 Enrollment ID: I20140407002096 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alyssa M Hardy |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417376856 PECOS PAC ID: 8729211222 Enrollment ID: I20140508000649 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kevin Daniel Englund |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740576768 PECOS PAC ID: 3173793031 Enrollment ID: I20140520002274 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jake R Foley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912330150 PECOS PAC ID: 0749403780 Enrollment ID: I20140521000494 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alison Lindstrom Buck |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1225357411 PECOS PAC ID: 0749414498 Enrollment ID: I20140715002324 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Staci Baker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396158309 PECOS PAC ID: 7315164498 Enrollment ID: I20140813002196 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erik J Peterson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1174766505 PECOS PAC ID: 5395969786 Enrollment ID: I20140829001812 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David M Bowman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982018743 PECOS PAC ID: 8527287895 Enrollment ID: I20140918001126 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gregory J Gunderson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649426438 PECOS PAC ID: 2567530744 Enrollment ID: I20140923002092 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Matthew S Butterfield |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1629209598 PECOS PAC ID: 5395981633 Enrollment ID: I20140929002045 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan M Hauff |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518308956 PECOS PAC ID: 7214157064 Enrollment ID: I20140930001676 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Courtney L Kovacs |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528477197 PECOS PAC ID: 0547480964 Enrollment ID: I20141008000069 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kimberly L Gustafson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154722346 PECOS PAC ID: 0840410163 Enrollment ID: I20141008000451 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Maria S Hoglund |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790194363 PECOS PAC ID: 7416177704 Enrollment ID: I20141009000123 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kyle R Sell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437567682 PECOS PAC ID: 7315168499 Enrollment ID: I20141015001595 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Keyla J Guenther |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184023517 PECOS PAC ID: 5991926958 Enrollment ID: I20141016002306 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bridgett A Bonte-chun |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1861764557 PECOS PAC ID: 0941451074 Enrollment ID: I20141027000238 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jacquelyn L Conley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447694013 PECOS PAC ID: 3971724162 Enrollment ID: I20141103000710 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Angela L Hauth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013311463 PECOS PAC ID: 4789806498 Enrollment ID: I20141113001102 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elissa A Cohen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720374242 PECOS PAC ID: 2365612215 Enrollment ID: I20141216000336 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Leigh L Marasco |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1497160196 PECOS PAC ID: 8729301247 Enrollment ID: I20150107002498 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eva G Martinez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295131357 PECOS PAC ID: 5092030437 Enrollment ID: I20150206000934 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael A Steiner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376931527 PECOS PAC ID: 5294050373 Enrollment ID: I20150212000558 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Calvin Mai |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689062515 PECOS PAC ID: 2769707884 Enrollment ID: I20150212002019 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Leah Toth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376712885 PECOS PAC ID: 0042396806 Enrollment ID: I20150226000967 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ting Ting Brenner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437547213 PECOS PAC ID: 8123344538 Enrollment ID: I20150302002230 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael A Shirilla |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205977576 PECOS PAC ID: 7810153590 Enrollment ID: I20150423001526 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rachael L Ottum |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043643505 PECOS PAC ID: 0042530081 Enrollment ID: I20150514002502 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jessica T Thueringer |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1497073852 PECOS PAC ID: 9133440456 Enrollment ID: I20150623001481 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | David Charles Eggert |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1003058496 PECOS PAC ID: 3577780535 Enrollment ID: I20150713001051 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katrina Kneeskern |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619356409 PECOS PAC ID: 7214241249 Enrollment ID: I20150804004022 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jenna E Walker |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245614247 PECOS PAC ID: 0042525024 Enrollment ID: I20150820009607 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robin J Ou Yang |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1164736195 PECOS PAC ID: 7113232109 Enrollment ID: I20150820009921 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joy A Hasseler |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1265721906 PECOS PAC ID: 2466767371 Enrollment ID: I20150820010816 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristina L Withers |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760726053 PECOS PAC ID: 9032363270 Enrollment ID: I20150825002900 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katelyn M Cayton |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740666742 PECOS PAC ID: 8325354822 Enrollment ID: I20150828001476 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer P Bradley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194101402 PECOS PAC ID: 5193031631 Enrollment ID: I20150831000213 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott J Gorham |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831575299 PECOS PAC ID: 2062728462 Enrollment ID: I20150831002389 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer L Smidl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508233230 PECOS PAC ID: 3072820026 Enrollment ID: I20150923002375 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lindsay B Snyder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558744631 PECOS PAC ID: 8123338183 Enrollment ID: I20151104001187 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nathan K Proft |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528438207 PECOS PAC ID: 7113237074 Enrollment ID: I20151104001659 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Meredith Saylor Baker |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1023245701 PECOS PAC ID: 9739328964 Enrollment ID: I20151215001505 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Luann K Lerud |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205802576 PECOS PAC ID: 4486563228 Enrollment ID: I20160129002204 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brett W Petersen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295008761 PECOS PAC ID: 6901102862 Enrollment ID: I20160303000414 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amanda L Tschida-schirmers |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508007667 PECOS PAC ID: 3678879350 Enrollment ID: I20160307000483 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Danielle M Stark |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255798757 PECOS PAC ID: 0244536522 Enrollment ID: I20160314000090 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Virginia C Borrman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1467810135 PECOS PAC ID: 3173829207 Enrollment ID: I20160315002334 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Marc W Nolan |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1679916837 PECOS PAC ID: 8224335633 Enrollment ID: I20160330001915 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ann M Frett |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902838576 PECOS PAC ID: 8426356510 Enrollment ID: I20160405001896 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Charlene N Bunger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508864406 PECOS PAC ID: 7517975840 Enrollment ID: I20160412001150 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Izaak P Schafer |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629432919 PECOS PAC ID: 1850699083 Enrollment ID: I20160421000005 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carin J Wulf |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730153792 PECOS PAC ID: 9436448727 Enrollment ID: I20160509002430 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lilliana B Lind |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659627719 PECOS PAC ID: 7214227933 Enrollment ID: I20160608000396 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bradley J Leavelle |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376577874 PECOS PAC ID: 6709020233 Enrollment ID: I20160613001745 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole Williams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013377308 PECOS PAC ID: 3678865102 Enrollment ID: I20160701001120 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Terrence Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396827937 PECOS PAC ID: 3274825716 Enrollment ID: I20160701001553 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jacqueline C Gierok |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1447688528 PECOS PAC ID: 4183916125 Enrollment ID: I20160712000618 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nathan R Wanderman |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1033598321 PECOS PAC ID: 1052622701 Enrollment ID: I20160726001438 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah Bou Malham |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1720392590 PECOS PAC ID: 8426280124 Enrollment ID: I20160802000164 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Janet T Lee |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1790958775 PECOS PAC ID: 0749584464 Enrollment ID: I20160804001671 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | John Clinton Tanner |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1780882662 PECOS PAC ID: 2062656580 Enrollment ID: I20160809001843 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gregory M Deyak |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255783999 PECOS PAC ID: 9739473968 Enrollment ID: I20160810001216 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristen A Akervik |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1467804252 PECOS PAC ID: 7517251705 Enrollment ID: I20160811000103 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Luke A Wernberg |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912350265 PECOS PAC ID: 5193010338 Enrollment ID: I20160826000303 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Byram J Nash |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114471141 PECOS PAC ID: 2668767724 Enrollment ID: I20160829001033 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel C Allen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932653979 PECOS PAC ID: 5890080998 Enrollment ID: I20160829002174 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Zachary P Arntson |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1396056842 PECOS PAC ID: 2163730706 Enrollment ID: I20160830000797 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Emily M Schnabl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891147989 PECOS PAC ID: 0143516153 Enrollment ID: I20160830003163 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer Sackrison Metherd |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1093072340 PECOS PAC ID: 2860621422 Enrollment ID: I20160912001262 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megan Erickson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184177479 PECOS PAC ID: 8123314416 Enrollment ID: I20160913001737 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tegan Nelson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194970251 PECOS PAC ID: 8224325212 Enrollment ID: I20160919001751 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nathaniel L Peterson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104373117 PECOS PAC ID: 2163719162 Enrollment ID: I20160919002081 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan W Hess |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1548467970 PECOS PAC ID: 4385890391 Enrollment ID: I20160920000085 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jessica M Heimkes |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265718100 PECOS PAC ID: 4789971359 Enrollment ID: I20160926000708 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel B Stark |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790230688 PECOS PAC ID: 9436446903 Enrollment ID: I20160927001758 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Braidy S Solie |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144774456 PECOS PAC ID: 2860789096 Enrollment ID: I20161003000197 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan H Schoenecker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205289899 PECOS PAC ID: 1850688029 Enrollment ID: I20161003001511 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sally A Hutson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1639423528 PECOS PAC ID: 7012205842 Enrollment ID: I20161011003111 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brittany E Wirth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831646348 PECOS PAC ID: 6901194612 Enrollment ID: I20161013000066 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew J Kremer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417402637 PECOS PAC ID: 3779871140 Enrollment ID: I20161018001590 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katelyn Marie Kubat Money |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184179780 PECOS PAC ID: 2062700362 Enrollment ID: I20161019000061 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Krystan A Coyle |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265493977 PECOS PAC ID: 3072527407 Enrollment ID: I20161025001069 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lukas D Cash |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1326580549 PECOS PAC ID: 5698054310 Enrollment ID: I20161118002358 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megan Michelle Nelson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902359219 PECOS PAC ID: 0345529970 Enrollment ID: I20161122000995 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lisa S Carlson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811430952 PECOS PAC ID: 2668752700 Enrollment ID: I20161207002688 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joseph S Bert |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1760776512 PECOS PAC ID: 8022241652 Enrollment ID: I20161219000400 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jaimi Anderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598730541 PECOS PAC ID: 9830470798 Enrollment ID: I20170109000505 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Heidi Sprang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548237274 PECOS PAC ID: 5890076756 Enrollment ID: I20170109000696 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Vicki I Buth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013982180 PECOS PAC ID: 5597046458 Enrollment ID: I20170109000802 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Grant W Blasczyk |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811439748 PECOS PAC ID: 2365724721 Enrollment ID: I20170119000532 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ashley M Rundle |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720468697 PECOS PAC ID: 9133404171 Enrollment ID: I20170314001395 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sara M Norseng |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619349214 PECOS PAC ID: 7719263490 Enrollment ID: I20170412000248 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Justin R Nicol |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043601784 PECOS PAC ID: 3375829971 Enrollment ID: I20170414000104 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cecily I Jensen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1083149512 PECOS PAC ID: 6204113822 Enrollment ID: I20170509002619 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric Christian Busse |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1861780942 PECOS PAC ID: 1850522533 Enrollment ID: I20170531001443 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brianna M Bosma |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831629849 PECOS PAC ID: 3476822297 Enrollment ID: I20170710002116 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kurt J Duncan |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1952693749 PECOS PAC ID: 4486886728 Enrollment ID: I20170717003452 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Charles P Jude |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1285010546 PECOS PAC ID: 2062782436 Enrollment ID: I20170717003706 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aaron R Solseth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902951494 PECOS PAC ID: 5092085811 Enrollment ID: I20170726002496 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bryan Dale Den Hartog |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1043299738 PECOS PAC ID: 5092608190 Enrollment ID: I20170731001925 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kaci M Traczyk |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154850659 PECOS PAC ID: 8921379272 Enrollment ID: I20170803003503 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nels D Leafblad |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1457715955 PECOS PAC ID: 8224321351 Enrollment ID: I20170821002067 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jaimi L Weber |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1336594498 PECOS PAC ID: 4587958095 Enrollment ID: I20170821003523 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kyle J Flagstad |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982131165 PECOS PAC ID: 6800169632 Enrollment ID: I20170830001402 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bradley Keller |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710402854 PECOS PAC ID: 6800160805 Enrollment ID: I20170914000721 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mary A Koch |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164949715 PECOS PAC ID: 8426322462 Enrollment ID: I20170914002719 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jozef Murar |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1841583259 PECOS PAC ID: 6002111978 Enrollment ID: I20170920000215 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melanie R Kielsa |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891222709 PECOS PAC ID: 4183998776 Enrollment ID: I20170920002494 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kevin J Murphy |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1023533999 PECOS PAC ID: 8325312937 Enrollment ID: I20170920003604 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jacob A Wendt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730621095 PECOS PAC ID: 1759655293 Enrollment ID: I20170921001178 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bethany R Baron |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306362140 PECOS PAC ID: 0446524912 Enrollment ID: I20170921002231 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth Keller |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588187462 PECOS PAC ID: 1658645973 Enrollment ID: I20170925002006 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erin T Pederson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477074854 PECOS PAC ID: 1254605397 Enrollment ID: I20170927004515 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole M Giebenhain |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255858205 PECOS PAC ID: 7810262987 Enrollment ID: I20170929001875 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elise S Lee |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275058505 PECOS PAC ID: 7719252790 Enrollment ID: I20170929002567 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Breanna N Smith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386161552 PECOS PAC ID: 4082989546 Enrollment ID: I20171009003222 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cynthia M Mayorga |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871566307 PECOS PAC ID: 7416222682 Enrollment ID: I20171013002943 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Suzanne G Weinberger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053384511 PECOS PAC ID: 5698040863 Enrollment ID: I20171013002979 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Clair Bernard |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700300381 PECOS PAC ID: 7012281785 Enrollment ID: I20171023001407 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thomas Broback |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1063930493 PECOS PAC ID: 0941576433 Enrollment ID: I20171027002584 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrea M Wendt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1922544162 PECOS PAC ID: 3779849062 Enrollment ID: I20171101002687 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anna N Hunter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649243171 PECOS PAC ID: 0648536300 Enrollment ID: I20171113002273 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Dylan R Moen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457860348 PECOS PAC ID: 5395001861 Enrollment ID: I20171116000860 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Timothy T Hafemeyer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1639467988 PECOS PAC ID: 6305103391 Enrollment ID: I20171129002301 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian R Holst |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1356850515 PECOS PAC ID: 1658638481 Enrollment ID: I20171201002139 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tripti Joshi |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225556178 PECOS PAC ID: 0941567507 Enrollment ID: I20171206002911 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katie L Ehlen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700138195 PECOS PAC ID: 3779841747 Enrollment ID: I20171220002281 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tyler J Douglass |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942714035 PECOS PAC ID: 1052679693 Enrollment ID: I20180103001029 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexander P Niznik |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174043012 PECOS PAC ID: 6507125390 Enrollment ID: I20180124002781 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer L Schwab |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1407016892 PECOS PAC ID: 6608025499 Enrollment ID: I20180205001206 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alison M Weaver |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275069676 PECOS PAC ID: 6800154709 Enrollment ID: I20180212000591 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Roger L Burtraw |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588062988 PECOS PAC ID: 5395005235 Enrollment ID: I20180214000870 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amanda Mickelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245744234 PECOS PAC ID: 9739440058 Enrollment ID: I20180301002443 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian R Linville |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427468735 PECOS PAC ID: 2668693029 Enrollment ID: I20180420002482 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kaitlyn A Lindahl |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1548761729 PECOS PAC ID: 4880959048 Enrollment ID: I20180517003069 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joshua Allan Albarado |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1124517677 PECOS PAC ID: 2062767452 Enrollment ID: I20180626003691 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole Renee Salfer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982195236 PECOS PAC ID: 3870849813 Enrollment ID: I20180706000094 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brooke M Deshler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154620847 PECOS PAC ID: 5597933416 Enrollment ID: I20180706000996 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joanna Vermedahl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275024903 PECOS PAC ID: 8224385240 Enrollment ID: I20180723002126 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jesse C Heaton |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508356361 PECOS PAC ID: 4385991108 Enrollment ID: I20180724003373 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Dustin M Schlangen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306299888 PECOS PAC ID: 0648567875 Enrollment ID: I20180726000760 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Samantha M Crowley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518451004 PECOS PAC ID: 3779830443 Enrollment ID: I20180726000996 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robalee Lynn Wanderman |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1689106429 PECOS PAC ID: 8426320490 Enrollment ID: I20180801002505 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gabrielle M Wienke |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710431846 PECOS PAC ID: 5193073310 Enrollment ID: I20180804000125 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Paige E Persch |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1285052027 PECOS PAC ID: 2860780491 Enrollment ID: I20180807000123 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Chee N Vang |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043720451 PECOS PAC ID: 8123376084 Enrollment ID: I20180809000006 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott J Cichos |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790261923 PECOS PAC ID: 0941558779 Enrollment ID: I20180809005430 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Caitlin R Dewitt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679069751 PECOS PAC ID: 1557619277 Enrollment ID: I20180811000048 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan P Cole |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366671406 PECOS PAC ID: 8527210624 Enrollment ID: I20180811000193 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sharon Frattalone |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1891994067 PECOS PAC ID: 0042508590 Enrollment ID: I20180814001411 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megan Louise Mcchesney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992296222 PECOS PAC ID: 6103175567 Enrollment ID: I20180817000608 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexandria M Ellingson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790105088 PECOS PAC ID: 4284939455 Enrollment ID: I20180820003275 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Samuel J Arnold |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013447499 PECOS PAC ID: 3577812601 Enrollment ID: I20180822001265 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kathryn A Medinger |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518443373 PECOS PAC ID: 1557610649 Enrollment ID: I20180822003717 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexa M Horning |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750868352 PECOS PAC ID: 9032468061 Enrollment ID: I20180823002133 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hailey R Fuechtmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649758079 PECOS PAC ID: 4587913496 Enrollment ID: I20180824002033 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Caitlin Jurgens |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255708079 PECOS PAC ID: 2466768619 Enrollment ID: I20180828002420 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anne Marie E Sirany |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1306136411 PECOS PAC ID: 5193020246 Enrollment ID: I20180831000308 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rachel E Wilson |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1437680048 PECOS PAC ID: 0244503225 Enrollment ID: I20180905001441 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian J Gahlon |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407341696 PECOS PAC ID: 8820349590 Enrollment ID: I20180919000639 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian F Allen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679950968 PECOS PAC ID: 1153680566 Enrollment ID: I20180919002856 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Samuel W Carlson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1184151524 PECOS PAC ID: 5597038380 Enrollment ID: I20181002002417 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kayla Marie Tackmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700369790 PECOS PAC ID: 5597017467 Enrollment ID: I20181004002070 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Daniel P Bergevin-smith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1316394307 PECOS PAC ID: 2264784446 Enrollment ID: I20181017000397 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Edward G Bowron |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518440023 PECOS PAC ID: 9335491414 Enrollment ID: I20181018000627 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James A Palmer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093231714 PECOS PAC ID: 4981957883 Enrollment ID: I20181023001326 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Janna M Neher |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093299729 PECOS PAC ID: 5991058349 Enrollment ID: I20181101000008 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Marie Y Armstrong |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144608480 PECOS PAC ID: 5698087369 Enrollment ID: I20181102000711 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeffrey J Lapanta |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932637345 PECOS PAC ID: 2668425810 Enrollment ID: I20181203001863 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher J Vandergriff |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1033686258 PECOS PAC ID: 8224372933 Enrollment ID: I20181206003341 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Blake R Huppert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114494606 PECOS PAC ID: 4183968761 Enrollment ID: I20181208000455 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erika Janet Hachey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588146732 PECOS PAC ID: 8527303825 Enrollment ID: I20181214000036 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kayley L Gamm |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1184986010 PECOS PAC ID: 3173868155 Enrollment ID: I20181219001663 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jill Marie Garnier |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1780848317 PECOS PAC ID: 8325228612 Enrollment ID: I20181224000063 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Meghan F Stommes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366842734 PECOS PAC ID: 2860739745 Enrollment ID: I20190130002702 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lauren N Lehmkuhl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134683907 PECOS PAC ID: 2466792932 Enrollment ID: I20190319002897 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ashleigh J Kratz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831657428 PECOS PAC ID: 7214278621 Enrollment ID: I20190412000780 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael Hans Johnson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1902063829 PECOS PAC ID: 3577704915 Enrollment ID: I20190429000963 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Denise Small |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699200626 PECOS PAC ID: 5698018133 Enrollment ID: I20190523002327 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexander T Barney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386193035 PECOS PAC ID: 0749568723 Enrollment ID: I20190531000039 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sharon L Zehender |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1558597021 PECOS PAC ID: 2264571538 Enrollment ID: I20190604000066 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole Rae Tombers |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396175444 PECOS PAC ID: 5496088668 Enrollment ID: I20190604001424 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Weston Obrycki |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396303947 PECOS PAC ID: 9739412768 Enrollment ID: I20190606001893 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bryan Alm |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659939494 PECOS PAC ID: 3678806189 Enrollment ID: I20190614000153 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Emily Ann Yee |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790205805 PECOS PAC ID: 1658605506 Enrollment ID: I20190626001506 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth Susan George |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871987230 PECOS PAC ID: 2860704319 Enrollment ID: I20190627002371 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher Suilmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760047815 PECOS PAC ID: 8426382144 Enrollment ID: I20190628000673 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kathleen A Heimer |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902384159 PECOS PAC ID: 4587998190 Enrollment ID: I20190701001588 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Natalie N Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790341865 PECOS PAC ID: 8224363395 Enrollment ID: I20190711001115 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Taylor N Kuhn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982263190 PECOS PAC ID: 8921333824 Enrollment ID: I20190715003207 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan T Ness |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1881255248 PECOS PAC ID: 4688909245 Enrollment ID: I20190718001656 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew C Ockuly |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1245646983 PECOS PAC ID: 2163770090 Enrollment ID: I20190722003050 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Taylor B Schiffler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1326600065 PECOS PAC ID: 3577899939 Enrollment ID: I20190724000714 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer L Falcon |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1548820616 PECOS PAC ID: 7719213172 Enrollment ID: I20190724000826 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | William M Engasser |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1366856445 PECOS PAC ID: 2466678057 Enrollment ID: I20190729001513 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nathan James Jacobson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1639674112 PECOS PAC ID: 7113274952 Enrollment ID: I20190806000948 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Emily F Midura |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1104115484 PECOS PAC ID: 2668612508 Enrollment ID: I20190812000977 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rachel E Kneeland |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1053773887 PECOS PAC ID: 6002109105 Enrollment ID: I20190822001728 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Dana L Cox |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790339497 PECOS PAC ID: 4082942941 Enrollment ID: I20190830000180 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katie M Haferman |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306145081 PECOS PAC ID: 9739418245 Enrollment ID: I20190909003473 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aneel Damle |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1376863274 PECOS PAC ID: 3779882105 Enrollment ID: I20190911002949 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christine M Taylor |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770992042 PECOS PAC ID: 7719216027 Enrollment ID: I20190912000538 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melinda Ellen Stack |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1215223490 PECOS PAC ID: 8921301961 Enrollment ID: I20190920000349 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristi L Demars |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790332294 PECOS PAC ID: 0749510501 Enrollment ID: I20190923001039 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jenna L Coghlan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760039234 PECOS PAC ID: 6901136373 Enrollment ID: I20190927000253 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelli F Finn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871148742 PECOS PAC ID: 0840520235 Enrollment ID: I20190927001155 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alyssa N Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902153422 PECOS PAC ID: 2860723467 Enrollment ID: I20191014000236 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jay V Ellerbusch |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689151185 PECOS PAC ID: 3870824253 Enrollment ID: I20191016002080 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexander Kuczwarskyj |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437718558 PECOS PAC ID: 1355679879 Enrollment ID: I20191030000744 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Callie R Hogan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1922655547 PECOS PAC ID: 8123450350 Enrollment ID: I20191108002201 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kera Noel Madsen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831381003 PECOS PAC ID: 2961835095 Enrollment ID: I20191204000788 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jenna L Szpek |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679074546 PECOS PAC ID: 8527491240 Enrollment ID: I20191210001553 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Stephanie A Ham |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013554682 PECOS PAC ID: 8224463898 Enrollment ID: I20200109000816 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erik T Krueger |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215576145 PECOS PAC ID: 9537594742 Enrollment ID: I20200116001465 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tamara L Larsen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174155519 PECOS PAC ID: 2163850827 Enrollment ID: I20200312001026 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nichole A Meyer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164514170 PECOS PAC ID: 7810947942 Enrollment ID: I20200401001554 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kendra G Bartsch |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275593493 PECOS PAC ID: 9335248814 Enrollment ID: I20200428001303 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Adan M Omar |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1699169615 PECOS PAC ID: 8224388111 Enrollment ID: I20200616001642 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan J Hoel |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1194135863 PECOS PAC ID: 6406150218 Enrollment ID: I20200714003071 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Eric S Miller |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1134514201 PECOS PAC ID: 9537453196 Enrollment ID: I20200803002718 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bethany A Reuter |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649898909 PECOS PAC ID: 9830514090 Enrollment ID: I20200805000279 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Taylor J Ridley |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1477973246 PECOS PAC ID: 6507161759 Enrollment ID: I20200818001069 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Marcus J Mittelsteadt |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1215347117 PECOS PAC ID: 5092019810 Enrollment ID: I20200819002566 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Taylor N.e. Carlson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588275242 PECOS PAC ID: 1658798921 Enrollment ID: I20200901001682 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katelyn O'keefe |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1083075865 PECOS PAC ID: 4789002049 Enrollment ID: I20200918000022 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christine Marie Ellison |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841804952 PECOS PAC ID: 7719306299 Enrollment ID: I20201001003537 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sean Deane Lejonvarn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003426230 PECOS PAC ID: 6305265760 Enrollment ID: I20201005000451 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megan T Ocel |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336750488 PECOS PAC ID: 3870913064 Enrollment ID: I20201008001414 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark Steven Weigand |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1346847597 PECOS PAC ID: 2365862109 Enrollment ID: I20201019000020 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carli Marie Walker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164029419 PECOS PAC ID: 4789004326 Enrollment ID: I20201020001250 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Grant Douglas Stevens |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841642816 PECOS PAC ID: 6204122575 Enrollment ID: I20201028002437 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeremy O'keefe |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093371775 PECOS PAC ID: 9436483054 Enrollment ID: I20201104000572 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Benjamin Sam |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629639893 PECOS PAC ID: 8628488285 Enrollment ID: I20201110002103 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Shelby N Webber |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003476094 PECOS PAC ID: 4789014945 Enrollment ID: I20210114000183 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lauren Kensey Taylor |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437748613 PECOS PAC ID: 0345654646 Enrollment ID: I20210128000128 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelsey J Majerus |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427575208 PECOS PAC ID: 4688947708 Enrollment ID: I20210220000118 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Madalyn Marie Carlin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821630658 PECOS PAC ID: 2961817846 Enrollment ID: I20210227000153 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Margaret Michele Dolan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1477077824 PECOS PAC ID: 7618384637 Enrollment ID: I20210318000935 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kaela Michael Colvard |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1770177164 PECOS PAC ID: 7416365168 Enrollment ID: I20210416001351 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Breanna Jean Lohn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538545322 PECOS PAC ID: 5890002588 Enrollment ID: I20210426002738 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Adam Urick |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912424037 PECOS PAC ID: 4284970369 Enrollment ID: I20210429001619 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark Robert Loscheider |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396327581 PECOS PAC ID: 4183033111 Enrollment ID: I20210504001783 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kimberly Candice Abrahams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720065311 PECOS PAC ID: 6406875947 Enrollment ID: I20210513002820 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robin Jean Prugno |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1891148037 PECOS PAC ID: 9537497557 Enrollment ID: I20210519002868 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melinda L Zhang |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1760918353 PECOS PAC ID: 9537431192 Enrollment ID: I20210520002274 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hui Zhang |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1134581200 PECOS PAC ID: 1153615018 Enrollment ID: I20210528001184 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lucas Blanchard |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932774874 PECOS PAC ID: 9436558996 Enrollment ID: I20210603001131 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brian Ishola |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730755075 PECOS PAC ID: 2163822594 Enrollment ID: I20210607001951 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Matthew Stewart |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1568038149 PECOS PAC ID: 2264832401 Enrollment ID: I20210610000429 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Adam J Michalik |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1558713115 PECOS PAC ID: 6305197872 Enrollment ID: I20210623001815 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Deirdre Michelle Moes |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427289099 PECOS PAC ID: 7416358635 Enrollment ID: I20210625001044 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rachel M.r. Gorham |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1487278214 PECOS PAC ID: 9133521669 Enrollment ID: I20210707001109 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hanwen Wong |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609443266 PECOS PAC ID: 2264834043 Enrollment ID: I20210715004085 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ellen Marie Thornburg |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518556380 PECOS PAC ID: 8729481080 Enrollment ID: I20210723000970 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anthony Rikberg |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1578135190 PECOS PAC ID: 4385047687 Enrollment ID: I20210723002497 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrew M Schmiesing |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1659758613 PECOS PAC ID: 8224333455 Enrollment ID: I20210729002077 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Isabella H Kane |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134792575 PECOS PAC ID: 5698178481 Enrollment ID: I20210731000008 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher Eric Honstad |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1174917009 PECOS PAC ID: 5991086209 Enrollment ID: I20210812000331 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Leah Nicole Hammer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508430323 PECOS PAC ID: 0143624007 Enrollment ID: I20210814000007 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hayley Anne Accola |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134642705 PECOS PAC ID: 8527463819 Enrollment ID: I20210825001230 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Emma Jane Butzer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043815988 PECOS PAC ID: 1850796921 Enrollment ID: I20210827000976 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Fernando E Espinosa |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265107700 PECOS PAC ID: 1355747700 Enrollment ID: I20210909002351 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nirvan K Dharampaul |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780275164 PECOS PAC ID: 7719396324 Enrollment ID: I20210914003461 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aaron Philip Bloom |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1174985733 PECOS PAC ID: 7315239365 Enrollment ID: I20210917002419 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Theresa C Mcdevitt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093397085 PECOS PAC ID: 6709283013 Enrollment ID: I20210928003240 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kristen Anne Latta |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1699204248 PECOS PAC ID: 8123399979 Enrollment ID: I20211001001679 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anna C Morrison |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376214320 PECOS PAC ID: 5991103863 Enrollment ID: I20211006002541 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thane David Widmer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972175149 PECOS PAC ID: 6406254036 Enrollment ID: I20211012000647 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Allison Marie Erdmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699372151 PECOS PAC ID: 7113347477 Enrollment ID: I20211015000889 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rachel R Krautbauer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1568133106 PECOS PAC ID: 3577961861 Enrollment ID: I20211019000026 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Bradley A Hise |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841964178 PECOS PAC ID: 6204224934 Enrollment ID: I20211028001675 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Caroline Anne Bennett Rey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538821764 PECOS PAC ID: 0840688297 Enrollment ID: I20211104000068 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mark R Wilcox |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629505359 PECOS PAC ID: 6608143151 Enrollment ID: I20211109000419 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Robert Matthew Brenner |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1366862971 PECOS PAC ID: 1951605765 Enrollment ID: I20211118002082 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicholas R Tschida |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457016735 PECOS PAC ID: 9931599420 Enrollment ID: I20211123002224 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sarah Derosier |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689113045 PECOS PAC ID: 1658761994 Enrollment ID: I20211201000833 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Molly Elizabeth Miller |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629104815 PECOS PAC ID: 0244621837 Enrollment ID: I20211215000229 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alicia Ann Lembrich |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1912668880 PECOS PAC ID: 9436541091 Enrollment ID: I20220112001039 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hannah Marie Martin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1023788528 PECOS PAC ID: 6608268602 Enrollment ID: I20220125002517 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lucas Allen Grossoehme |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1477134336 PECOS PAC ID: 2769875392 Enrollment ID: I20220203000907 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Delores J Mcdonald |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770917502 PECOS PAC ID: 3072747724 Enrollment ID: I20220209000776 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Hannah Lynn Stackpool |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205351475 PECOS PAC ID: 8527453588 Enrollment ID: I20220310000732 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelsey Irene Nowak |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134526650 PECOS PAC ID: 8820484819 Enrollment ID: I20220330002339 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jordan Van Eps |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225655566 PECOS PAC ID: 9234552100 Enrollment ID: I20220401001952 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelli Denk Bosholm |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811079486 PECOS PAC ID: 8325435217 Enrollment ID: I20220422002157 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kyle D Morgenstern |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1285167064 PECOS PAC ID: 6103195946 Enrollment ID: I20220513001521 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Christopher J. Traynor |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1285162776 PECOS PAC ID: 0345518007 Enrollment ID: I20220520000295 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Parker J Hanson |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1538665641 PECOS PAC ID: 1254688377 Enrollment ID: I20220520001600 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rebecca Lynn Carruthers |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1568659076 PECOS PAC ID: 9931587284 Enrollment ID: I20220527001816 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mackenzie R Thayer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1053818252 PECOS PAC ID: 3072861160 Enrollment ID: I20220602000085 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Megan Lowe |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699439687 PECOS PAC ID: 5698153401 Enrollment ID: I20220607003038 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Janice Gerber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528721701 PECOS PAC ID: 4284012964 Enrollment ID: I20220608002542 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy K Holst |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992253397 PECOS PAC ID: 6709164791 Enrollment ID: I20220609000166 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mckenzie N Tirrel |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306585252 PECOS PAC ID: 8022497445 Enrollment ID: I20220615001156 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexis Mashl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982336715 PECOS PAC ID: 2062893738 Enrollment ID: I20220713001652 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Pedro Zavala |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386224947 PECOS PAC ID: 5193106037 Enrollment ID: I20220722002221 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Haley N Roed |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487385159 PECOS PAC ID: 5193106961 Enrollment ID: I20220726000697 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melinda Fjosne |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952785297 PECOS PAC ID: 8426430208 Enrollment ID: I20220727001500 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jorge Eduardo Diaz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871255398 PECOS PAC ID: 8325420771 Enrollment ID: I20220801002465 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Zoe L Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760154199 PECOS PAC ID: 6204218662 Enrollment ID: I20220801003080 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Pridvi G Kandagatla |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1346668555 PECOS PAC ID: 4981829850 Enrollment ID: I20220806000730 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | James B Bircher |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1053771204 PECOS PAC ID: 7012207947 Enrollment ID: I20220808001873 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexander Hickmann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629704135 PECOS PAC ID: 0547643389 Enrollment ID: I20220811002595 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth G Hermes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1568197044 PECOS PAC ID: 7012390313 Enrollment ID: I20220819000503 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan Z Lee |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386379055 PECOS PAC ID: 1658754817 Enrollment ID: I20220820000263 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lindsay Chrest |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295463065 PECOS PAC ID: 1759765704 Enrollment ID: I20220825001304 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Shania Gonzales |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932832011 PECOS PAC ID: 7214311182 Enrollment ID: I20220826002612 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Riley C Simpson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851027585 PECOS PAC ID: 5890179444 Enrollment ID: I20220830004015 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeremiah David Johnson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1386031433 PECOS PAC ID: 5496057002 Enrollment ID: I20220902002442 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Justin T Eglseder |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1124525779 PECOS PAC ID: 5294110318 Enrollment ID: I20220909001888 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Shannon V Ahern |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720715568 PECOS PAC ID: 4587049572 Enrollment ID: I20220912001612 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Brooke Dummer |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1609500552 PECOS PAC ID: 4981089364 Enrollment ID: I20220921002248 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rebecca P Z Krause |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508341314 PECOS PAC ID: 2365789724 Enrollment ID: I20220922003582 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cassandra Woodland |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043753494 PECOS PAC ID: 2567745516 Enrollment ID: I20221003000615 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Quinn M Garner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194390815 PECOS PAC ID: 1254731573 Enrollment ID: I20221011000441 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elise N Olsen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891413530 PECOS PAC ID: 6901272061 Enrollment ID: I20221014002572 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Rebecca D Fedie |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629046602 PECOS PAC ID: 7517974777 Enrollment ID: I20221102002693 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carley M Bowe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063149532 PECOS PAC ID: 7911375001 Enrollment ID: I20221121002508 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elizabeth A Narigon |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1619565058 PECOS PAC ID: 0840669198 Enrollment ID: I20221208003192 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Philip Punnoose |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1801523782 PECOS PAC ID: 4688043623 Enrollment ID: I20221213002589 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer Lynn Cogswell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750093696 PECOS PAC ID: 7416327556 Enrollment ID: I20230105001490 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katherine Harris |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1639881410 PECOS PAC ID: 6204209141 Enrollment ID: I20230224000071 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Stefani M Neubeck |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1558947853 PECOS PAC ID: 0840663472 Enrollment ID: I20230302000721 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Elle M Kingsley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205496601 PECOS PAC ID: 8729451273 Enrollment ID: I20230302001864 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Benjamin A Resnick |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306542832 PECOS PAC ID: 8820461205 Enrollment ID: I20230306001771 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Zachary Thomas Eenhuis |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487144762 PECOS PAC ID: 3971976051 Enrollment ID: I20230310002297 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Natalie R Giese |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720786015 PECOS PAC ID: 9931573524 Enrollment ID: I20230322001141 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aundrea D Rainville |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1063625648 PECOS PAC ID: 8022140607 Enrollment ID: I20230322001782 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cailin E Forsythe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487352431 PECOS PAC ID: 5496129959 Enrollment ID: I20230323001933 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Pamela Burgess |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1558593061 PECOS PAC ID: 1951609346 Enrollment ID: I20230330000283 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Colleen Fafinski |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1356040901 PECOS PAC ID: 2163897257 Enrollment ID: I20230403000891 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kylie M Ryan |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1588110225 PECOS PAC ID: 0547635450 Enrollment ID: I20230406001768 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tara Lynn Doerr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528770419 PECOS PAC ID: 3375918105 Enrollment ID: I20230410002218 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michelle Renee Jarman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407557366 PECOS PAC ID: 1254706815 Enrollment ID: I20230412002416 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Alexandria A Sweeney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659937662 PECOS PAC ID: 8325413776 Enrollment ID: I20230417002126 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jennifer Vu Brion |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1124729736 PECOS PAC ID: 7113382193 Enrollment ID: I20230426001390 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Mackenzie A Zorn |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992450720 PECOS PAC ID: 0840655585 Enrollment ID: I20230502000819 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tracie Lynn Reamer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114620689 PECOS PAC ID: 3072978402 Enrollment ID: I20230508001423 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Aubrey Krahn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710618376 PECOS PAC ID: 8527448315 Enrollment ID: I20230512002423 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melissa M Glynn |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659075281 PECOS PAC ID: 3476919598 Enrollment ID: I20230516001836 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jonathan-erle Reid |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1811553241 PECOS PAC ID: 7517394471 Enrollment ID: I20230523002922 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Cody Suchla |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417648759 PECOS PAC ID: 9133586159 Enrollment ID: I20230607001288 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Lori Post |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1225586001 PECOS PAC ID: 6103107958 Enrollment ID: I20230609002329 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Chelsea Ann Bayer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1831570100 PECOS PAC ID: 1254645849 Enrollment ID: I20230609003082 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kyler Kinnamon |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699465484 PECOS PAC ID: 6709244536 Enrollment ID: I20230626002940 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Gregory L Scallon |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1326481797 PECOS PAC ID: 0042514853 Enrollment ID: I20230627002157 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Thomas John Fischer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396211488 PECOS PAC ID: 7719346246 Enrollment ID: I20230630002680 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Anthony D Simons |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1285326207 PECOS PAC ID: 5698134120 Enrollment ID: I20230630002782 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Amy J Brown |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154014322 PECOS PAC ID: 6800255225 Enrollment ID: I20230703002389 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Julia Black |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912681610 PECOS PAC ID: 6901265164 Enrollment ID: I20230706000757 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Andrea M Gredvig |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518650852 PECOS PAC ID: 0042679243 Enrollment ID: I20230706002131 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Derek Allen Plath |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104501808 PECOS PAC ID: 9537528666 Enrollment ID: I20230706003572 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Etasha M Bhatt |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1417335183 PECOS PAC ID: 2163726977 Enrollment ID: I20230712000244 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Benjamin L Andre |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972180271 PECOS PAC ID: 8426458498 Enrollment ID: I20230713000627 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Scott Richardson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942992102 PECOS PAC ID: 3971963695 Enrollment ID: I20230713000711 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Erik L Slette |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1134610132 PECOS PAC ID: 5395105050 Enrollment ID: I20230713002162 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Derick W Hansen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1568156008 PECOS PAC ID: 5890155485 Enrollment ID: I20230713003620 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Shashank S Dwivedi |
|---|---|
| Provider Type | Practitioner - Hand Surgery |
| Provider Identifiers | NPI Number: 1841648755 PECOS PAC ID: 4880989375 Enrollment ID: I20230720002607 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Joseph Michael Nessler |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1699201038 PECOS PAC ID: 5395015309 Enrollment ID: I20230721000701 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Katherine Marie Watson |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1356703276 PECOS PAC ID: 8325334485 Enrollment ID: I20230724000632 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Briana Kay Linnerooth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407547664 PECOS PAC ID: 1052771995 Enrollment ID: I20230724002647 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Quiara Gordon |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1568019719 PECOS PAC ID: 1456712397 Enrollment ID: I20230725003112 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Samantha R Witta |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1528520103 PECOS PAC ID: 7618338377 Enrollment ID: I20230728000644 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kathryn A Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134803885 PECOS PAC ID: 3173984556 Enrollment ID: I20230801003981 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jeffrey Anton Gilbertson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1598293706 PECOS PAC ID: 3375811037 Enrollment ID: I20230803001574 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Zachary E Pressman |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1710418660 PECOS PAC ID: 6608146378 Enrollment ID: I20230807001800 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan C Nielsen |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1891134359 PECOS PAC ID: 1658665591 Enrollment ID: I20230809002646 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jarred C Frisk |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114618287 PECOS PAC ID: 7719349364 Enrollment ID: I20230814001251 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ahmed Attia |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1447844899 PECOS PAC ID: 0648678466 Enrollment ID: I20230816000999 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Michael Picken |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104509223 PECOS PAC ID: 8527421601 Enrollment ID: I20230823002007 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Halley Fine |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366121584 PECOS PAC ID: 2264895655 Enrollment ID: I20230901001010 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Desmond J Fulton |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538847272 PECOS PAC ID: 6103280318 Enrollment ID: I20230906003282 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Tyler R Williamson |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1225561939 PECOS PAC ID: 2769751429 Enrollment ID: I20230911002681 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Carla N Kinnunen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528740602 PECOS PAC ID: 0749644623 Enrollment ID: I20230911003131 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Ryan P Yelle |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821329756 PECOS PAC ID: 5193860435 Enrollment ID: I20230913001175 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Molly Kay Stark |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902689292 PECOS PAC ID: 3375907090 Enrollment ID: I20230914000820 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Catrina O Fjerstad |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265216949 PECOS PAC ID: 0749644367 Enrollment ID: I20230915001372 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Allyson C Sima |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255014940 PECOS PAC ID: 1456715887 Enrollment ID: I20230918002880 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Natalie M Riutta |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609653468 PECOS PAC ID: 3779937446 Enrollment ID: I20230928002973 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Sierra N Wells |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1033995733 PECOS PAC ID: 7113371600 Enrollment ID: I20231003000919 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Corey Martin Larson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336689363 PECOS PAC ID: 7214324805 Enrollment ID: I20231018000938 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kayla M Gerasimou |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851023592 PECOS PAC ID: 2961858303 Enrollment ID: I20231021000635 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Kelley F Grotting |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033890181 PECOS PAC ID: 5597111831 Enrollment ID: I20231024000345 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Jordan Mills |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093592479 PECOS PAC ID: 1153777966 Enrollment ID: I20231031002264 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Melissa Vanderlinde |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396517397 PECOS PAC ID: 3779934559 Enrollment ID: I20240105001010 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Angela M Tullbane |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1689211526 PECOS PAC ID: 5496105017 Enrollment ID: I20240122004021 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicole Werts |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720410590 PECOS PAC ID: 3678926870 Enrollment ID: I20240124001199 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Keri Mills |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1932675998 PECOS PAC ID: 5395108260 Enrollment ID: I20240202002015 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
| Provider Name | Nicholas R Del Giudice |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225747652 PECOS PAC ID: 2769853928 Enrollment ID: I20240206002207 |
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
News Archive
About 10 percent of fathers experience prenatal or postpartum depression, with rates being highest in the 3 to 6 month postpartum period, according to an analysis of previous research appearing in the May 19 issue of JAMA, a theme issue on mental health.
By altering the expression of a single - albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.
Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the Journal of Alzheimer's Disease.
Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.
› Verified 1 days ago
Twin Cities Foot And Ankle Clinic Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5851 Duluth St, Suite 101, Golden Valley, MN 55422 Phone: 763-546-1718 Fax: 763-546-1943 | |
Golden Valley Chiropractic Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5661 Duluth St, Golden Valley, MN 55422 Phone: 612-378-1050 | |
Hospitalist Medicine Physicians Of Hennepin County, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1300 Hidden Lakes Pkwy, Golden Valley, MN 55422 Phone: 330-493-4443 Fax: 330-493-8677 | |
Back In Shape Chiropractic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 669 Winnetka Ave N, Suite 202, Golden Valley, MN 55427 Phone: 763-595-9096 Fax: 763-595-0291 | |
Pathways Chiropractic Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5851 Duluth St, Suite 115, Golden Valley, MN 55422 Phone: 763-634-5892 | |
The Wellness Center At General Mills Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9000 Plymouth Ave N, Golden Valley, MN 55427 Phone: 763-764-6000 |